Status:
UNKNOWN
Procalcitonin as a Marker of Infection in Cancer Patients
Lead Sponsor:
Herlev Hospital
Collaborating Sponsors:
Rigshospitalet, Denmark
Conditions:
Infections
Cancer
Eligibility:
All Genders
Brief Summary
Infections pose a serious threat to cancer patients in chemotherapy. Prompt diagnosis and treatment is of paramount importance as infections may be life-threatening in immune-compromised individuals. ...
Detailed Description
Purpose of the study: Is pro calcitonin a marker for bacterial infection in cancer patients? Is pro calcitonin better than C-reactive-protein to identify cancer patients with a bacterial infection? ...
Eligibility Criteria
Inclusion
- Gr I: In-patients in anticancer therapy for a solid cancer with confirmed bacterial infection Gr II: Patients in anticancer therapy without any signs or symptoms of infection.
- Both groups: Informed consent
Exclusion
- None
- \-
Key Trial Info
Start Date :
February 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2012
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01227109
Start Date
February 1 2011
End Date
October 1 2012
Last Update
October 25 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Herlev University Hospital
Copenhagen, Denmark, DK-2730 Herlev
2
Herlev hospital
Herlev, Denmark, dk-2730